Bioluminescence imaging of Hepatitis C virus NS3/4A serine protease activity in cells and living animals

被引:22
作者
Wang, Licui [1 ]
Fu, Qiuxia [1 ]
Dong, Yafeng [1 ]
Zhou, Yong [1 ]
Jia, Shuaizheng [1 ]
Du, Juan [1 ]
Zhao, Fang [1 ]
Wang, Yingli [1 ]
Wang, Xiaohui [1 ]
Peng, Jianchun [1 ]
Yang, Shuhua [1 ]
Zhan, Linsheng [1 ]
机构
[1] Beijing Inst Transfus Med, Lab Blood Borne Virus, Beijing 100850, Peoples R China
基金
国家高技术研究发展计划(863计划);
关键词
NS3/4A protease; Split firefly luciferase complementation strategy; In vivo imaging; RNA REPLICATION; IN-VIVO; INFECTION; CULTURE; ASSAY; INTERFERENCE; REPLICON; VIREMIA; LINES;
D O I
10.1016/j.antiviral.2010.04.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The lack of robust small animal models has been an obstacle to the screening of Hepatitis C virus (HCV) NS3/4A protease inhibitors in vivo. Here, we described a reporter assay system for in vivo noninvasive imaging of NS3/4A serine protease activity using split firefly luciferase complementation strategy. The reporter construct ANIuc(NS5A/B)BCluc constitutes the split N- and C-terminal fragments of luciferase, fused to interacting peptides, pepA and pepB, respectively, with an intervening HCV NS3/4A cleavage motif of NSSA/B. we proved that the reporter molecule could be proteolytically cleaved by NS3/4A at the NS5A/B motif in cells and living animals. Association of pepA and pepB brought inactive fragments of luciferase into close proximity, thereby restoring bioluminescence activity. The increase in luciferase activity was proportional to the dose of active NS3/4A protease. The ANIuc(NS5A/B)BCluc reporter also could be used to detect the activity of NS3/4A-specific shRNA and IFN-alpha. Therefore, the reporter assay system using split firefly luciferase complementation strategy should prove useful for evaluating NS3/4A protease activity in cells and living animals. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:50 / 56
页数:7
相关论文
共 50 条
  • [31] Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a
    Guo, Zhuyan
    Black, Stuart
    Hu, Yuan
    McMonagle, Patricia
    Ingravallo, Paul
    Chase, Robert
    Curry, Stephanie
    Asante-Appiah, Ernest
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2017, 292 (15) : 6202 - 6212
  • [32] Characterization of NS3 protease from an Egyptian HCV genotype 4a isolate
    Bahgat, Mahmoud Mohamed
    Ibrahim, Ahmed Atef
    Abd-Elshafy, Dina Nadeem
    Mesalam, Ahmed Atef
    Gewaid, Hossam Eid
    Ismaeil, Amany Abd-Elghany
    El-Waseef, Ahmed Mohamed
    Maghraby, Amany Sayed
    Barakat, Ahmed Barakat
    El-Far, Mohamed Abd-Elhafez
    Ghanem, Hossam El-Din Ahmed
    Mohamed, Amro Mahmoud
    Ali, Mohamed Ahmed
    ARCHIVES OF VIROLOGY, 2009, 154 (10) : 1649 - 1657
  • [33] GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo
    Zhai, Pei-bin
    Qing, Jie
    Li, Ben
    Zhang, Lin-qi
    Ma, Lan
    Chen, Li
    ACTA PHARMACOLOGICA SINICA, 2018, 39 (11) : 1746 - 1752
  • [34] Discovery of a series of novel compounds with moderate anti-hepatitis C virus NS3 protease activity in vitro
    Shi, Fangyuan
    Zhang, Yingjie
    Xu, Wenfang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (17) : 5539 - 5545
  • [35] PCR-Based In Vitro Synthesis of Hepatitis C Virus NS3 Protease for Rapid Phenotypic Resistance Testing of Protease Inhibitors
    Qiao, Jinjuan
    Yu, Junping
    Yang, Hang
    Wei, Hongping
    JOURNAL OF CLINICAL MICROBIOLOGY, 2014, 52 (04) : 1139 - 1145
  • [36] The resistance mutation R155K in the NS3/4A protease of hepatitis C virus also leads the virus to escape from HLA-A*68-restricted CD8 T cells
    Salloum, Shadi
    Kluge, Silvia F.
    Kim, Arthur Y.
    Roggendorf, Michael
    Timm, Joerg
    ANTIVIRAL RESEARCH, 2010, 87 (02) : 272 - 275
  • [37] The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons
    Lahser, Frederick C.
    Bystol, Karin
    Curry, Stephanie
    McMonagle, Patricia
    Xia, Ellen
    Ingravallo, Paul
    Chase, Robert
    Liu, Rong
    Black, Todd
    Hazuda, Daria
    Howe, Anita Y. M.
    Asante-Appiah, Ernest
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 2954 - 2964
  • [38] Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451
    Yang, Huiling
    Robinson, Margaret
    Corsa, Amoreena C.
    Peng, Betty
    Cheng, Guofeng
    Tian, Yang
    Wang, Yujin
    Pakdaman, Rowchanak
    Shen, Marian
    Qi, Xiaoping
    Mo, Hongmei
    Tay, Chin
    Krawczyk, Steve
    Sheng, X. Christopher
    Kim, Choung U.
    Yang, Chris
    Delaney, William E.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (02) : 647 - 653
  • [39] Novel, potent, and orally bioavailable phosphinic acid inhibitors of the hepatitis C virus NS3 protease
    Clarke, Michael O.
    Chen, Xiaowu
    Cho, Aesop
    Delaney, William E.
    Doerffler, Edward
    Fardis, Maria
    Ji, Mingzhe
    Mertzman, Michael
    Pakdaman, Rowchanak
    Pyun, Hyun-Jun
    Rowe, Tanisha
    Yang, Cheng Y.
    Sheng, X. Christopher
    Kim, Choung U.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (12) : 3568 - 3572
  • [40] Interplay between NS3 protease and human La protein regulates translation-replication switch of Hepatitis C virus
    Ray, Upasana
    Das, Saumitra
    SCIENTIFIC REPORTS, 2011, 1